Advertisement

Effectiveness of Medifast supplements combined with obesity pharmacotherapy: A clinical program evaluation

  • C. K. Haddock
  • W. S. C. PostonEmail author
  • J. P. Foreyt
  • J. J. DiBartolomeo
  • P. O. Warner
Original Research Paper

Abstract

PURPOSE: To evaluate the long-term impact of Medifast meal-replacement supplements (MMRS) combined with appetite suppressant medication (ASM) among participants who received 52 weeks of treatment. METHODS: We conducted a systematic program evaluation of weight loss data from a medically-supervised weight control program combining the use of MMRS and ASM. Data were obtained and analyzed from 1,351 patient (BMI=25) medical charts who had participated for at least 12 weeks of treatment. Outcomes included weight loss (kg) and percent weight loss from baseline and at 12, 24, and 52 weeks. Both completers and intention-to-treat analyses were conducted. Completers’ (i.e., those with complete data for 52 weeks) outcomes were evaluated after stratification for reported adherence to the MMRS and ASM. RESULTS: Participants who completed 52 weeks of treatment experienced substantial weight losses at 12 (-9.4±5.7 kg), 24 (-12.0±8.1 kg), and 52 weeks (-12.4±9.2 kg) and all measures were significantly different from baseline weight (p<0.001 for all contrasts) for both true completers (n=324) and for ITT analysis (n=1,351). Fifty percent of patients remained in the program at 24 weeks and nearly 25% were still participating at one year. CONCLUSIONS: This weight loss program using a combination of MMRS and ASM produced significant and sustained weight losses at 52 weeks. Results were better than those typically reported for obesity pharmacotherapy in both short- and long-term studies and also better than those reported for partial meal replacement programs. Program retention at one year was similar to that reported in many controlled drug trials and better than most commercial programs reported in the literature.

Key words

Obesity primary care weight loss meal replacement pharmacotherapy 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Marketdata Enterprises 2005. The US weight loss & diet control market. 8th edition. URL: http://www.marketresearch.com/product/display.asp?product=1075148. Accessed 11/14/2006.
  2. 2.
    Tsai A.G., Wadden T.A.: Systematic review: An evaluation of major commercial weight loss programs in the United States. Ann. Intern. Med., 142, 56–66, 2005.PubMedCrossRefGoogle Scholar
  3. 3.
    Wang S.S., Wadden T.A., Womble L.G., Nonas C.A.: What consumers want to know about commercial weight-loss programs: A pilot investigation. Obes. Res., 11, 48–53, 2003.PubMedCrossRefGoogle Scholar
  4. 4.
    Cheskin L.J., Mitchell A.M., Lewis R.A., Jhaveri A.D., Yep M.A.: Efficacy of two diet plans designed for people with type 2 diabetes on weight and health measures. Presented at the American Diabetes Association’s 65th Annual Scientific Session, San Diego, CA, 2005.Google Scholar
  5. 5.
    Heshka S., Anderson J.W., Atkinson R.L., Greenway F.L., Hill J.O., Phinney S.D., Kolotkin R.L., Miller-Kovach K., Pi-Sunyer F.X.: Weight loss with self-help compared with a structured commercial program: A randomized trial. JAMA, 289, 1792–1798, 2003.PubMedCrossRefGoogle Scholar
  6. 6.
    Medifast 2006. Corporate website. URL: http://www.medifast1.com/webpromo/. Accessed 12/11/2006.
  7. 7.
    Truby H., Baic S., deLooy A., Fox K.R., Livingstone M.B., Logan C.M., MacDonald I.A., Morgan L.M., Taylor M.A., Millward D.J.: Randomized controlled trial of four commercial weight loss programmes in the UK: initial findings from the BBC diet trials. B.M.J., 332, 1309–1314, 2006.CrossRefGoogle Scholar
  8. 8.
    Wadden T.A., Berkowitz R.I., Womble L.G., Sarwer D.B., Phelan S., Cato R.K., Hesson L.A., Osei S.Y., Kaplan R., Stunkard A.J.: Randomized trial of lifestyle modification and pharmacotherapy for obesity. N. Engl. J. Med., 353, 2111–2120, 2005.PubMedCrossRefGoogle Scholar
  9. 9.
    Poston W.S.C., Haddock C.K., Pinkston M.M., Pace P., Reeves R.S., Karakoc N., Jones P., Foreyt J.P.: Evaluation of a primary care-oriented brief counselling intervention for obesity with and without orlistat. J. Intern. Med., 260, 388–398, 2006.PubMedCrossRefGoogle Scholar
  10. 10.
    Padwal R., Li S.K., Lau D.C.W.: Long-term pharmacotherapy for overweight and obesity: A systematic review and meta-analysis of randomized controlled trials. Int. J. Obes. Relat. Metab. Disord., 27, 1437–1446, 2003.PubMedCrossRefGoogle Scholar
  11. 11.
    Volkmar F.R., Stunkard A.J., Woolston J., Bailey R.A.: High attrition rates in commercial weight loss reduction programs. Arch. Intern. Med., 141, 426–428, 1981.PubMedCrossRefGoogle Scholar
  12. 12.
    Finley C.E., Barlow C.E., Greenway F.L., Rock C.L., Rolls B.J., Blair S.N.: Retention rates and weight loss in a commercial weight loss program. Int. J. Obes. Relat. Metab. Disord., 31, 292–298, 2007.CrossRefGoogle Scholar
  13. 13.
    Haddock C.K., Poston W.S.C., Dill P.L., Foreyt J.P., Ericsson M.: Pharmacotherapy for obesity: A quantitative analysis of four decades of published randomized clinical trials. Int. J. Obes. Relat. Metab. Disord., 26, 262–273, 2002.PubMedCrossRefGoogle Scholar
  14. 14.
    Heymsfield S.B., van Mierlo C.A.J., van der Knaap H.C.M., Heo M., Frier H.I.: Weight management using a meal replacement strategy: Meta and pooling analysis from six studies. Int. J. Obes. Relat. Metab. Disord., 27, 537–549, 2003.PubMedCrossRefGoogle Scholar

Copyright information

© Editrice Kurtis 2008

Authors and Affiliations

  • C. K. Haddock
    • 1
  • W. S. C. Poston
    • 1
    Email author
  • J. P. Foreyt
    • 2
  • J. J. DiBartolomeo
    • 3
  • P. O. Warner
    • 4
  1. 1.Kansas City School of MedicineUniversity of MissouriUSA
  2. 2.Baylor College of MedicineUSA
  3. 3.Medifast Inc.USA
  4. 4.New Dimensions Medical GroupUSA

Personalised recommendations